Company Description
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.
It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression.
It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 4, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Raymond Joseph Tesi M.D. |
Contact Details
Address: 225 Ne Mizner Blvd, Suite 640 Boca Raton, Florida 33432 United States | |
| Phone | (858) 964-3720 |
| Website | inmunebio.com |
Stock Details
| Ticker Symbol | INMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001711754 |
| CUSIP Number | 45782T105 |
| ISIN Number | US45782T1051 |
| Employer ID | 47-5205835 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, President, Chief Executive Officer, Chief Medical Officer and Chairman |
| David J. Moss M.B.A. | Chief Financial Officer, Treasurer and Secretary |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Chief Scientific Officer and Chief Manufacturing Officer |
| Joshua S. Schoonover Esq. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 29, 2024 | DEF 14A | Other definitive proxy statements |
| May 23, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K | Current Report |
| May 13, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 30, 2024 | 8-K | Current Report |